AUS
NZ
UK
CA
USA
IND
Mesoblast Limited (ASX:MSB), the Australian biotech firm specialising in cell-based therapies, has applied for ASX quotation of 2,250,000 newly issued fully paid ordinary shares following the exercise of employee share options. These shares were issued on 23 June 2026, with the quotation application submitted on 14 July 2026. This issuance results from the vesting and exercise of employee options and increases Mesoblast’s total quoted ordinary shares to 1,296,862,776. Investors should consider this update as part of the company’s ongoing employee incentive initiatives within its capital management strategy.
Key Highlights
- Mesoblast Limited (ASX:MSB) is an Australian biotechnology company developing cell-based medicines
- Applied for ASX quotation of 2,250,000 fully paid ordinary shares issued under its employee share option plan
- Shares issued on 23 June 2026; Appendix 2A lodged with ASX on 14 July 2026
- Total quoted ordinary shares on issue will reach 1,296,862,776 after quotation
- Investors should monitor future employee incentive plan activity and changes to unquoted securities including options and warrants
Mesoblast Seeks ASX Listing for 2.25 Million Shares Issued Under Employee Incentive Scheme
Mesoblast Limited has formally applied for the ASX quotation of 2,250,000 fully paid ordinary shares by lodging an Appendix 2A on 14 July 2026. The shares, issued on 23 June 2026, belong to an existing class of securities traded under the ASX code MSB. The company confirmed these shares rank equally with all existing fully paid ordinary shares, carrying identical rights and entitlements from the issue date.
The shares were issued to the employee share plan trustee following the exercise of previously granted options under Mesoblast’s employee share option plan. These options had met all vesting conditions before exercise. Such share issuances are standard remuneration features in Australian biotech and tech companies, designed to attract and retain specialised talent. The terms of Mesoblast’s employee incentive scheme were detailed in the Notice of Meeting released on 27 October 2025.
Employee Share Option Plan Governs Vesting and Exercise Process
Mesoblast’s employee share option plan grants options to employees as part of its remuneration and retention strategy. Options carry vesting conditions that must be met before employees can exercise them to receive shares. The company confirmed the exercised options had satisfied all vesting criteria, resulting in the issuance of 2,250,000 fully paid ordinary shares.
The shares were issued to the employee share plan trustee, a common administrative practice among Australian listed companies. The trustee holds shares on behalf of participants until transfer or disposition per plan rules. The exercise consideration per security was recorded at zero Australian dollars, reflecting the structure of the options rather than a commercial sale. Full scheme terms are publicly available via the Notice of Meeting lodged on 27 October 2025 on the ASX platform.
Total Quoted Ordinary Shares Surpass 1.29 Billion Post-Issuance
Following the quotation of these 2,250,000 shares, Mesoblast’s total quoted ordinary fully paid shares will be 1,296,862,776. This figure is generated through the Appendix 2A process and may not fully capture concurrent capital changes if other forms are being processed simultaneously by ASX. Nonetheless, it provides the most current publicly available total quoted share count.
The addition of 2.25 million shares to a base exceeding 1.29 billion represents a modest increase. The company did not specify the percentage dilution impact; investors should analyse the total share count to assess dilution. The new shares hold equal rights to dividends, capital returns, and voting alongside existing shares.
Substantial Unquoted Securities Including Options and Warrants Remain
Mesoblast holds a significant number of unquoted securities. As disclosed, these include 86,258,114 options expiring on various dates and exercise prices under ASX code MSBAI. The company also has multiple warrant classes outstanding: 2,000,000 MSBAA warrants, 15,027,327 MSBAO warrants, 884,838 MSBAP ADS warrants, and 2,000,000 MSBAB warrants.
These unquoted options and warrants represent potential future share issuances if exercised, which could dilute existing shareholders. The company did not provide guidance on exercise timing, pricing, or likelihood. Investors should review prior ASX disclosures for full terms and conditions.
Listing Rule 7.2 Exception Applies to Employee Share Issuance
Mesoblast confirmed this share issuance is covered by Listing Rule 7.2 Exception 13, meaning shareholder approval under ASX Listing Rule 7.1 is not required. This exception applies to shares issued under an employee incentive scheme previously approved by shareholders, enabling efficient administration without repeated shareholder meetings.
This standard exception facilitates timely issuance of shares upon option exercises, reducing administrative burden for both the company and plan participants. The employee incentive scheme was approved at the shareholder meeting detailed in the Notice of Meeting dated 27 October 2025.
About Mesoblast: A Global Cell Therapy Company Listed on ASX and NASDAQ
Mesoblast Limited, headquartered in Melbourne, Australia, develops allogeneic cell-based medicines derived from mesenchymal lineage cells. The company has extensive clinical programs targeting serious medical conditions and operates across Australia, the US, and international markets. Mesoblast is dual-listed on the ASX (ticker MSB) and NASDAQ via American Depositary Shares, explaining the presence of ADS warrants in its unquoted securities.
Its business model focuses on developing, obtaining regulatory approvals for, and commercialising proprietary cell therapy products. Employee incentive arrangements are a key part of attracting and retaining specialised scientific, clinical, and commercial staff. The employee share option plan referenced here is integral to this human capital strategy, with terms previously disclosed to shareholders in October 2025.
Concurrent Appendix 3G Filing Updates Unquoted Securities Post-Exercise
Alongside the Appendix 2A quotation application, Mesoblast lodged an Appendix 3G notification reflecting a reduction in total options outstanding, corresponding to those exercised into the 2,250,000 ordinary shares. This dual filing is standard for ASX-listed companies to update quoted and unquoted securities registers simultaneously.
The Appendix 3G enhances transparency around changes in unquoted securities, allowing investors to track option pool movements. The company did not disclose details on specific option tranches exercised, exercise prices, or identities of employees involved, other than confirming no key management personnel (KMP) or their associates participated in this issuance.
No Key Management Personnel Participated in 23 June 2026 Share Issuance
Mesoblast confirmed that none of the 2,250,000 shares issued on 23 June 2026 were allocated to KMP or their associates, fulfilling ASX Listing Rule disclosure requirements. This ensures transparency regarding share issuances that could benefit directors, executives, or influential individuals.
This confirmation supports governance-conscious investors monitoring related-party transactions and executive remuneration. While specific employees exercising options were not named, the exclusion of KMP aligns with ASX rules and corporate governance best practices. Detailed executive remuneration disclosures are available in the company’s latest annual and remuneration reports.
Investor Insights on Mesoblast’s Employee Plan Activity and Share Capital
For investors tracking Mesoblast’s capital structure, share issuances via employee option exercises represent typical incremental dilution for ASX-listed biotech firms. The 2.25 million shares issued here are small relative to the total quoted shares exceeding 1.29 billion. However, with over 86 million unquoted options and approximately 20 million warrants outstanding, investors should monitor future disclosures on exercises and quotations.
The immediate impact on Mesoblast’s share price from this update was unclear. Market reaction will depend on broader operational performance, clinical pipeline progress, and biotech sector conditions. Investors may focus more on upcoming clinical or commercial milestones than routine employee share plan issuances. No operational guidance or pipeline updates accompanied this announcement.
